Bendamustine - Eagle Pharmaceuticals

Drug Profile

Bendamustine - Eagle Pharmaceuticals

Alternative Names: Bendamustine 500mL; Bendamustine 50mL; Bendamustine II; Bendamustine rapid infusion; Bendamustine RI; Bendamustine RTD; Bendamustine shorter-infusion; Bendeka; EP-3101; EP-3102; RTD bendamustine

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eagle Pharmaceuticals
  • Class Antineoplastics; Benzimidazoles; Butyric acids; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules
  • Mechanism of Action Antimetabolites; Apoptosis stimulants; DNA cross linking agents; DNA synthesis inhibitors; Mitosis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Phase I Solid tumours

Most Recent Events

  • 20 Sep 2017 Bendamustine (ready-to-dilute and rapid infusion) - Eagle Pharmaceuticals licensed to SymBio Pharmaceuticals in Japan
  • 21 Mar 2017 Eagle Pharmaceuticals has patent protection for bendamustine in USA
  • 15 Mar 2017 Eagle pharmaceuticals has patents pending for bendamustine in USA and other foreign countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top